Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment of a retinal degenerative disease or tissue injury. Also disclosed herein are methods of treating a retinal degenerative disease or tissue injury, by administering to a subject in need of such treatment, a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: A method for treating a tendon injury includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

Abstract: A method for treating and/or preventing osteoarthritis includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

Abstract: A pharmaceutical composition or method for promoting meibomian gland regeneration or for treating/preventing dry eye syndrome includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF).

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or preventing a disease, disorder and/or a condition related to inflammation, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease or a condition related to angiogenesis. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to angiogenesis, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of an ocular disease, particularly, dry eye disease. Also disclosed herein are methods of treating and/or preventing an ocular disease by administering to a subject in need of such treatment a composition containing a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of an ocular disease, particularly, dry eye disease. Also disclosed herein are methods of treating and/or preventing an ocular disease by administering to a subject in need of such treatment a composition containing a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or preventing a disease, disorder and/or a condition related to inflammation, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease or a condition related to angiogenesis. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to angiogenesis, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: A method for treating alopecia and/or hair depigmentation includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-44 amino acid residues and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 16-35 of SEQ ID NO: 10. Also disclosed herein are pharmaceutical compositions containing the synthetic peptide; and uses thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in treating alopecia and/or hair depigmentation in a subject.

Abstract: A method for promoting muscle or tendon regeneration, and/or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.

Abstract: A method for preventing and/or ameliorating skin aging in a subject includes administering to the subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.

Abstract: A method for treating osteoarthritis in a subject includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.